source
- Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCCBradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.onclive · 2mo ago↗ source
- STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and moreHHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressantsSTAT · 2mo ago↗ source
- Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in MyelofibrosisAndrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.